Dec 4, 2024

Featuring perspectives from Dr Gloria Gerber, Dr Jamie Koprivnikar, Prof Alexander Röth and Dr Jamile M Shammo, including the following topics:

Introduction: Paroxysmal Nocturnal Hemoglobinuria (PNH) and the General Medical Oncologist

• Diagnosis of and myths and misperceptions about PNH (0:00)

Overview — Biology and Pathophysiology

• Role of complement activation in PNH; classification and clinical presentation (7:00)
• PNH treatments and their complement targets (21:37)

Current Management Approaches

• Mechanistic similarities and differences between crovalimab and other available C5 inhibitors; potential practical advantages of crovalimab (24:56)
• Timing for initiation of treatment for PNH (32:08)
• Management of clinically significant extravascular hemolysis and residual anemia in patients with PNH receiving C5 inhibitor therapy (43:08)
• Risk of evolution to aplastic anemia or myeloid malignancy (45:54)
• Clinical trial database establishing the efficacy and safety of the C5 complement inhibitors eculizumab and ravulizumab for PNH (48:47)
• Activity and safety of and clinical experience with crovalimab (53:03)
• Monitoring and management of PNH in pregnant patients (58:37)

Case Presentations

• Case: A woman in her early 30s who receives a new diagnosis of classical PNH with symptomatic anemia — Dr Gerber (1:03:44)
• Case: A man in his early 30s with PNH initially treated with eculizumab who is transitioned to ravulizumab — Dr Koprivnikar (1:17:32)
• Case: A woman in her early 50s with a remote history of aplastic anemia — Dr Gerber (1:32:24)
• Case: A woman in her late 20s with PNH receiving active C5 inhibitor therapy who wishes to discuss alternative treatment options — Dr Koprivnikar (1:38:00)

CME information and select publications